Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

0(0%)

Results Posted

60%(3 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_1

17%

Ph not_applicable

17%

Ph phase_2

33%

Ph phase_4

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

2(33.3%)

Phase 4Post-market surveillance

2(33.3%)

N/ANon-phased studies

1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(1)

Detailed Status

Completed5

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (16.7%)

Phase 22 (33.3%)

Phase 42 (33.3%)

N/A1 (16.7%)

Trials by Status

completed583%

terminated117%

Recent Activity

0 active trials

Showing 5 of 6

completednot_applicable

Clinical Trials (6)

Showing 6 of 6 trials

NCT04602689Not Applicable

Fibrin Glue After ESD for High Risk Patients of Bleeding

Completed

NCT02155725Phase 4

Fibrinogen in Haemorrhage of Delivery

Completed

NCT01283321Phase 2

RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery

Terminated

NCT00496262Phase 2

Human Fibrinogen - Pharmacokinetics

Completed

NCT01475344Phase 1

Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)

Completed

NCT01487837Phase 4

Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.

Completed

All 6 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 6